Jan 30, 2023
MEETING BRIEFS 
ASH 2022: Leukemia
The latest news from ASH 2022: Leukemia, including features, abstracts, information about the conference, and more.
Factors Associated With Improved COVID-19 Outcomes for CLL
Factors Associated With Improved COVID-19 Outcomes for CLL
Patients with chronic lymphocytic leukemia (CLL) infected with COVID-19 during the most recent...
Advertisement
PW QUIZ
Novel Therapy May Replace Standard-of-Care Prophylaxis for GVHD
Novel Therapy May Replace Standard-of-Care Prophylaxis for GVHD
Post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil outperformed...
Intensive Chemotherapy Prior to Allo-HCT in Rel/Ref AML?
Intensive Chemotherapy Prior to Allo-HCT in Rel/Ref AML?
Intensive chemotherapy, in advance of allogeneic hematopoietic cell transplantation (allo-HCT),...
Ibrutinib Plus Venetoclax Displays Long-Term Benefits in CLL
Ibrutinib Plus Venetoclax Displays Long-Term Benefits in CLL
The 5-year follow-up data of the CAPTIVATE study demonstrated that first-line ibrutinib plus...
High-Dose Methotrexate or Standard Interim Maintenance in Young Patients with ALL?
High-Dose Methotrexate or Standard Interim Maintenance in Young Patients with ALL?
High-dose methotrexate was not associated with a reduction in the risk for CNS relapse compared...
Promising Results for Triplet Therapy With Magrolimab in AML
Promising Results for Triplet Therapy With Magrolimab in AML
Triplet therapy of azacitidine, venetoclax, and magrolimab was safe as first-line therapy in...
Friday Satellite Symposia
Friday Satellite Symposia
FSS are industry-supported, CME-certified symposia. These sessions are not part of the official...
ASH Foundation Run & Walk
ASH Foundation Run & Walk
The ASH Foundation Run & Walk will start and finish on Convention Center Boulevard and...
Health and Safety Protocols
Health and Safety Protocols
Key Protocols: Vaccination will be required for all in-person meeting attendees. ASH is...
EXPLORE MORE
ASH Schedule At A Glance
Friday, December 9th 7:00 a.m.– 6:00 p.m. Registration open (for in-person participants) 7:00...
Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Secondary Hematological Malignancies
Patients with aggressive hematological malignancies and second primary malignancies can develop...
Initial Treatment for CLL/ SLL: Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab
For a study, researchers sought to determine if ibrutinib combined with fludarabine,...
Ibrutinib Treatment for CLL/SLL: Overall and Subgroup Results from the Third Interim Analysis of FIRE
FIRE is a noninterventional, multicenter observational trial of patients in France receiving...
CLL/SLL Patients: Real-World Outcomes with First-Line Ibrutinib (Ibr) VS. Chemoimmunotherapy (CIT)
With the development of cutting-edge drugs like Ibr, the treatment landscape for CLL/SLL has...
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
